HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Natco Pharma Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: May 04, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1182 as of 02 May 15:30.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 8535 crore as compare to the Sep '24 revenue of ₹ 8351 crore. This represent the growth of 2.2% The revenue of Natco Pharma Ltd for the Dec '24 is ₹ 651.1 crore as compare to the Sep '24 revenue of ₹ 1434 crore. This represent the decline of -54.62%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 2427 crore as compare to the Sep '24 ebitda of ₹ 2390 crore. This represent the growth of 1.56% The ebitda of Natco Pharma Ltd for the Dec '24 is ₹ 215.1 crore as compare to the Sep '24 ebitda of ₹ 868.1 crore. This represent the decline of -75.22%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1404 crore over 7 quarters. This represents a CAGR of -0.03% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 132.4 crore over 7 quarters. This represents a CAGR of -48.32% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys announces cessation of subsidiary in Louisiana

Dr. Reddy's Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successf...

Read more

24 Mar 2025 13:48

News

Dr Reddys Laboratories to conduct board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 9 M...

Read more

22 Mar 2025 11:01

News

Dr. Reddy's recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

Dr. Reddy's Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75%...

Read more

13 Mar 2025 18:46

News

Dr Reddys Laboratories allots 11,250 equity shares under ESOS

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powe...

Read more

06 Mar 2025 19:16

News

Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility

The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and confirmed ...

Read more

27 Feb 2025 09:57

News

Dr Reddys Laboratories allots 20,155 equity shares under ESOS

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fu...

Read more

14 Feb 2025 18:24

Natco Pharma Ltd News Hub

News

Natco Pharma update on launch of Risdiplam in India

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Comp...

Read more

08 Apr 2025 11:16

News

Natco Pharma Ltd up for fifth session

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 8...

Read more

07 Mar 2025 13:00

News

Natco Pharma Ltd soars 1.69%

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837...

Read more

25 Feb 2025 13:05

News

Natco Pharma slips as Q3 PAT slides 38% YoY to Rs 132 cr

Profit before tax in Q3 FY25 stood at Rs 163.7 crore, down 36.13% as against Rs 256.3 cror...

Read more

13 Feb 2025 11:11

News

Natco Pharma Ltd drops for fifth straight session

Natco Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 997, ...

Read more

13 Feb 2025 13:35

News

Natco Pharma Ltd leads losers in 'A' group

Orchid Pharma Ltd, Vijaya Diagnostic Centre Ltd, FDC Ltd and Aegis Logistics Ltd are among...

Read more

13 Feb 2025 15:00

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Natco Pharma Ltd?

Market cap of Dr Reddys Laboratories Ltd is 98,707 Cr while Market cap of Natco Pharma Ltd is 15,071 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Natco Pharma Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Natco Pharma Ltd?

As of May 4, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1182.9. On the other hand, Natco Pharma Ltd stock price is INR ₹841.45.

How do dividend payouts of Dr Reddys Laboratories Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions